Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy

Table 4 Prognostic factors in univariate analysis

	Response rate (%)	p	TTP (months)	p	OS (months)	p
Age		1.000		0.002		0.015
< 60 years	36.7		5.1		16.0
≥ 60 years	36.9		3.9		10.2
Gender		0.049		0.148		0.117
Male	42.1		4.8		13.9
Female	26.7		4.1		12.4
Previous operation		0.068		0.173		< 0.001
+	31.9		4.6		15.8
-	46.6		4.6		10.5
Lauren’s classification		0.042		0.194		0.157
Diffuse	20.0		4.1		13.1
Intestinal	48.0		6.4		19.9
Mixed	42.6		4.7		11.5
Unknown	26.7		3.9		13.3
Adjuvant chemotherapy		0.205		0.655		0.181
+	31.1		4.6		12.9
-	41.0		4.8		13.2
CEA		0.737		0.976		0.154
< 5 ng/ml	35.6		4.4		15.1
≥ 5 ng/ml	39.3		4.6		11.5
Number of metastasis		0.430		0.276		0.335
1	33.7		4.2		13.2
> 1	40.5		4.6		13.1
NLR		0.327		0.461		0.005
< 3	33.9		4.6		15.8
≥ 3	41.9		4.6		10.9
PLR		0.530		0.285		0.098
< 160	34.1		4.9		13.3
≥ 160	39.5		4.0		12.2
cNLR		0.349		< 0.001		< 0.001
< 3 → <3	35.1		4.9		17.3
<3 → ≥ 3	26.7		3.1		8.6
≥ 3 → < 3	37.5		5.3		11.9
≥ 3 → ≥ 3	57.1		2.4		4.6
cPLR		0.757		0.006		0.002
< 160 → <160	36.4		4.9		13.3
<160 → ≥160	27.3		5.3		10.6
≥ 160→ <160	38.2		5.6		16.9
≥ 160 → ≥ 160	40.4		3.4		10.9

CEA Carcinoembryonic antigen, NLR Neutrophil lymphocyte ratio, PLR Platelet lymphocyte ratio, cNLR Change of neutrophil lymphocyte ratio after 1 cycle of chemotherapy, cPLR Change of platelet lymphocyte ratio after 1 cycle of chemotherapy.

ISSN: 1471-2407